Quinine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - " w/ " to " with ") |
Neil.m.young (talk | contribs) (Text replacement - "8 mg" to "8mg") |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[Malaria]]=== | ===[[Malaria]]=== | ||
* | *648mg PO Q8h x 7 days | ||
*See [http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf CDC Recommendations] for full treatment recommendations | *See [http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf CDC Recommendations] for full treatment recommendations | ||
===[[Babesiosis]]=== | ===[[Babesiosis]]=== | ||
* | *648mg PO q6-8h x7-10 days | ||
*Use with [[Clindamycin]] | *Use with [[Clindamycin]] | ||
| Line 16: | Line 16: | ||
===[[Malaria]]=== | ===[[Malaria]]=== | ||
*30 mg/kg/day PO q8h x 3-7 days | *30 mg/kg/day PO q8h x 3-7 days | ||
*Max: | *Max: 648mg/dose | ||
*See [http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf CDC Recommendations] for full treatment recommendations | *See [http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf CDC Recommendations] for full treatment recommendations | ||
===[[Babesiosis]]=== | ===[[Babesiosis]]=== | ||
* | *8mg/kg PO q8h x 7-10 days | ||
*Max: | *Max: 648mg/dose | ||
*Use with [[Clindamycin]] | *Use with [[Clindamycin]] | ||
| Line 29: | Line 29: | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
***Severe chronic renal failure: | ***Severe chronic renal failure: 648mg PO x 1 then 324 mg PO q12h | ||
***If on HD give after dialysis | ***If on HD give after dialysis | ||
**Pediatric | **Pediatric | ||
Revision as of 18:11, 20 July 2016
General
- Type: Antimalarial
- Dosage Forms: PO 324 (IM and IV formulations available outside US)
- Common Trade Names: Qualaquin
Adult Dosing
Malaria
- 648mg PO Q8h x 7 days
- See CDC Recommendations for full treatment recommendations
Babesiosis
- 648mg PO q6-8h x7-10 days
- Use with Clindamycin
Pediatric Dosing
Malaria
- 30 mg/kg/day PO q8h x 3-7 days
- Max: 648mg/dose
- See CDC Recommendations for full treatment recommendations
Babesiosis
- 8mg/kg PO q8h x 7-10 days
- Max: 648mg/dose
- Use with Clindamycin
Special Populations
- Pregnancy Rating: C
- Lactation: Probably safe
- Renal Dosing
- Adult
- Severe chronic renal failure: 648mg PO x 1 then 324 mg PO q12h
- If on HD give after dialysis
- Pediatric
- Not defined
- Adult
- Hepatic Dosing
- Adult and Pediatric
- No adjustment for Child-Pugh Class A or B
- Avoid in Child-Pugh Class C
- Adult and Pediatric
Contraindications
Black Box Warnings
General
- Allergy to class/drug
- Allergy to mefloquine or quinidine
- Black water fever
- ITP/TTP/HUS
- Thrombocytopenia
- Glucose-6-Phosphate Deficiency (G6PD)
- Myasthenia gravis
- Optic neuritis
- QT prolongation/Congenital long QT syndrome
- Electrolyte abnormalities
- Bradycardia
- Ventricular arrhythmias
- CHF
- Recent MI
Caution
- Torsades de pointes
- Atrial fibrillation/Atrial flutter
- Pregnancy
- Hepatic impairment
Adverse Reactions
Serious
- Cinchonism
- QT prolongation
- Torsades de pointes
- Anaphylaxis
- Angioedema
- Bronchospasm
- Thrombocytopenia
- TTP/HUS
- Hemolytic anemia
- Black water fever
- Stevens-Johnson syndrome and toxic epidermal necrolysis
- Intestinal nephritis
- Renal impairment
- Hepatitis
- Leukopenia
- Neutropenia
- DIC
- Hypoglycemia
- Myasthenia gravis exacerbation
- Lupus
- Optic neuritis
- Blindness
- Deafness
Common
- Cinchonism
- Headache
- Vasodilation
- Diaphoresis
- Nausea/Vomiting
- Tinnitus
- Impaired hearing
- Vertigo
- Visual impairment
- Fever
- Flushing
- asthenia
- Rash
- Pruritus
- Urticaria
- Diarrhea
- Abdominal pain
- Photosensitivity
Pharmacology
- Half-life: 9-12 hours
- Metabolism: Liver 80%, CYP450
- Excretion: Urine
- Mechanism of Action: Unknown
Administration
- Give with food
See Also
References
- Epocrates